{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:22:18Z","timestamp":1778253738392,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:00:00Z","timestamp":1759017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003761","name":"Universitair Medisch Centrum Utrecht","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003761","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.urolonc.2025.09.023","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:33:16Z","timestamp":1761593596000},"page":"64.e15-64.e25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular subtyping of advanced bladder cancer patients and patient-derived organoids based on a 3-marker immunohistochemistry approach to evaluate chemotherapy sensitivity"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7281-5872","authenticated-orcid":false,"given":"Bastiaan J.","family":"Viergever","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba C.","family":"Zuidema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trudy","family":"Jonges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne J.","family":"Van Schelven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Westland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Kalkhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onno","family":"Kranenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-7982","authenticated-orcid":false,"given":"Richard P.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2025.09.023_bib0001","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.09.023_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic burden of bladder cancer across the European Union","author":"Leal","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.023_bib0003","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.09.023_bib0004","series-title":"Contemporary update on neoadjuvant therapy for bladder cancer","author":"Nguyen","year":"2017"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.023_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-11291-0","article-title":"Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer","volume":"7","author":"Thomsen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2025.09.023_bib0006","article-title":"Molecular tumor heterogeneity in muscle invasive bladder cancer: biomarkers, subtypes, and implications for therapy","volume":"000","author":"da Costa","year":"2018","journal-title":"Urol Oncol: Semin Orig Investig"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.023_bib0007","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.035","article-title":"EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort(dagger): under the auspices of the EAU-ESMO Guidelines Committees","volume":"77","author":"Witjes","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.09.023_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines","author":"Witjes","year":"2021","journal-title":"European Urology"},{"issue":"6","key":"10.1016\/j.urolonc.2025.09.023_bib0009","doi-asserted-by":"crossref","first-page":"177.e5","DOI":"10.1016\/j.urolonc.2024.01.027","article-title":"Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers","volume":"42","author":"Reike","year":"2024","journal-title":"Urol Oncol: Semin Orig Investig"},{"key":"10.1016\/j.urolonc.2025.09.023_bib0010","article-title":"The consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2018","journal-title":"bioRxiv"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.023_bib0011","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-220124","article-title":"What is a bladder cancer molecular subtype?","volume":"9","author":"H\u00f6glund","year":"2023","journal-title":"Bladder Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.023_bib0012","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1097\/PAS.0000000000002053","article-title":"International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: molecular Subtypes of bladder Cancer - Principles of classification and emerging clinical utility","volume":"48","author":"Warrick","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.urolonc.2025.09.023_bib0013","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/s41379-018-0096-5","article-title":"Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases","volume":"31","author":"Sj\u00f6dahl","year":"2018","journal-title":"Modern Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.023_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/srep38531","article-title":"FOXA1, GATA3 and PPAR\u0263 cooperate to drive luminal subtype in bladder cancer: a molecular analysis of established Human cell lines","volume":"6","author":"Warrick","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.urolonc.2025.09.023_bib0015","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrurol.2014.129","article-title":"Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer","volume":"11","author":"Choi","year":"2014","journal-title":"Nat Rev Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.09.023_bib0016","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.euf.2023.03.012","article-title":"Intratumoral heterogeneity of molecular subtypes in muscle-invasive bladder cancer\u2014An extensive multiregional immunohistochemical analysis","volume":"9","author":"Schallenberg","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.1016\/j.urolonc.2025.09.023_bib0017","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1369\/00221554221095530","article-title":"Immunohistochemical assays for bladder cancer molecular subtyping: optimizing parsimony and performance of Lund taxonomy classifiers","volume":"70","author":"Hardy","year":"2022","journal-title":"J Histochem Cytochemis"},{"issue":"5","key":"10.1016\/j.urolonc.2025.09.023_bib0018","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1002\/cam4.5324","article-title":"Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer","volume":"12","author":"Olah","year":"2023","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.urolonc.2025.09.023_bib0019","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","article-title":"Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes","volume":"81","author":"Sj\u00f6dahl","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.023_bib0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12894-025-01704-y","article-title":"GATA3 amplification is associated with high grade disease in non-invasive urothelial bladder cancer but unrelated to patient prognosis","volume":"25","author":"Plage","year":"2025","journal-title":"BMC Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.09.023_bib0021","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3390\/cancers14071692","article-title":"Molecular subtypes as a basis for stratified use of Neoadjuvant chemotherapy for muscle-invasive bladder cancer\u2014A narrative review","volume":"14","author":"Sj\u00f6dahl","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.023_bib0022","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.annonc.2024.09.008","article-title":"Basal\/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial","volume":"36","author":"Groeneveld","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.023_bib0023","article-title":"Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial","volume":"10","author":"Griffin","year":"2024","journal-title":"J Pathol: Clin Res"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.023_bib0024","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","article-title":"Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer","volume":"71","author":"Alfred Witjes","year":"2017","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.023_bib0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on non\u2013Muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.023_bib0026","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.celrep.2014.10.035","article-title":"Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes","volume":"9","author":"Biton","year":"2014","journal-title":"Cell Rep"},{"issue":"14","key":"10.1016\/j.urolonc.2025.09.023_bib0027","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.3390\/ijms23147898","article-title":"Prediction of response to cisplatin-based neoadjuvant chemotherapy of muscle-invasive bladder cancer patients by molecular subtyping including KRT and FGFR target gene assessment","volume":"23","author":"Ecke","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2025.09.023_bib0028","doi-asserted-by":"crossref","DOI":"10.1097\/PAI.0000000000001272","article-title":"Deciphering the molecular landscape of urothelial carcinoma: immunohistochemistry-based subtyping using 4 easily available antibodies for cost-effective stratification","author":"Indulkar","year":"2025","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.023_bib0029","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41416-023-02494-6","article-title":"Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation","volume":"130","author":"Viergever","year":"2024","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.023_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.43","article-title":"Complex heatmap visualization","volume":"1","author":"Gu","year":"2022","journal-title":"iMeta"},{"key":"10.1016\/j.urolonc.2025.09.023_bib0031","unstructured":"Wei T. and Simko V., \u201cR package \u2018corrplot\u2019: visualization of a correlation matrix.,\u201d https:\/\/github.com\/taiyun\/corrplot, Accessed January 6, 2025."},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.023_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-00628-5","article-title":"Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5\/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer","volume":"11","author":"Bejrananda","year":"2021","journal-title":"Sci Rep"},{"issue":"22","key":"10.1016\/j.urolonc.2025.09.023_bib0033","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3390\/diagnostics14222501","article-title":"The role of immunohistochemistry as a surrogate marker in molecular subtyping and classification of bladder cancer","volume":"14","author":"Cano Barbadilla","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.urolonc.2025.09.023_bib0034","doi-asserted-by":"crossref","first-page":"e2587","DOI":"10.6061\/clinics\/2021\/e2587","article-title":"Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: association with clinicopathological features and outcomes","volume":"76","author":"Ravanini","year":"2021","journal-title":"Clinics"},{"issue":"11","key":"10.1016\/j.urolonc.2025.09.023_bib0035","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00345-018-2332-5","article-title":"Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways","volume":"36","author":"Rouanne","year":"2018","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.023_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100398","article-title":"Deep learning-based H-score quantification of immunohistochemistry-stained images","volume":"37","author":"Wen","year":"2023","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.09.023_bib0037","doi-asserted-by":"crossref","first-page":"177.e5","DOI":"10.1016\/j.urolonc.2024.01.027","article-title":"Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers","volume":"42","author":"Reike","year":"2024","journal-title":"Urol Oncol: Semin Orig Investig"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.023_bib0038","first-page":"1","article-title":"Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.023_bib0039","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.urolonc.2025.09.023_bib0040","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jmoldx.2024.08.005","article-title":"A versatile and upgraded version of the LundTax classification algorithm applied to independent cohorts","volume":"26","author":"Cotillas","year":"2024","journal-title":"J Mol Diagn"},{"issue":"16","key":"10.1016\/j.urolonc.2025.09.023_bib0041","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-18-1106","article-title":"Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"25","author":"Seiler","year":"2019","journal-title":"Clin Ca Res"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.023_bib0042","article-title":"Patient-derived organoids as a predictive biomarker for treatment response in cancer patients","volume":"5","author":"Wensink","year":"2021","journal-title":"NPJ Precis Oncol"},{"issue":"6378","key":"10.1016\/j.urolonc.2025.09.023_bib0043","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.023_bib0044","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392500393X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392500393X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T12:13:36Z","timestamp":1768392816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392500393X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S107814392500393X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.09.023","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular subtyping of advanced bladder cancer patients and patient-derived organoids based on a 3-marker immunohistochemistry approach to evaluate chemotherapy sensitivity","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}